Skip to main content
. 2021 Sep 17;29(3):492–503. doi: 10.1038/s41418-021-00869-x

Fig. 2. TRAIL combined with CDK9 inhibition shows therapeutic efficacy in pancreatic organoids in vitro and in vivo.

Fig. 2

a, b Sytox-positive KPCY or KPC organoids were treated for 24 h with DMSO, iz-mTRAIL (1000 ng/ml) and/or dinaciclib (100 nM) and/or NVP-2 (100 nM) or with gemcitabine (1 μM). Scale bars, 200 µm (left panels). Cell viability of KPCY or KPC organoids was determined by CellTiter-Glo (right panels). Data are mean ± SEM, n ≥ 3. c Experimental protocol: iz-mTRAIL (5 mg/kg) and/or dinaciclib (30 mg/kg); and/or NVP-2 (5 mg/kg) or gemcitabine (50 mg/kg) or 200 µl buffer were administered intraperitoneally 7 days after subcutaneous injection of 1 × 106 KPC cells. d Histological analysis of KPC tumors and corresponding CK19 and AB/PAS stain. Black box indicates region enlarged on the bottom. e Tumor weight quantification at day 28. Dots represent individual mice. Error bars represent mean ± SEM.